Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

14.20 +0.81 (+6.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: 
Via Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept... 
Via FinancialNewsMedia
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
Photo by Raimond Klavins 
Via Benzinga
Fintech Focus For December 13, 2021
One Big Thing In Fintech: Understanding the fundamentals of a publicly-listed company can help with making more informed investment decisions. Still, many fail in conducting any... 
Via Benzinga
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning... 
Via Benzinga
BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’
Via Investor Brand Network
Topics Artificial Intelligence
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
FDA Shows Support For Development Of MindMed's Session Monitoring System
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) recently met with the US Food and Drug Administration (FDA) Center for Devices and... 
Via Benzinga
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
Photo by Michael Longmire on... 
Via Benzinga
MNMD Stock Pops Higher After MindMed Unveils ‘Psychedelic’ Data
MNMD stock is up today after MindMed reported positive findings on the interactions between psilocybin and an antidepressant. 
Via InvestorPlace
Antidepressants Can Be Used During Psilocybin Treatment, A New MindMed & Liechti Lab Study Finds
Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective... 
Via Benzinga
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market.... 
Via FinancialNewsMedia
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
3 Psychedelic Stocks for Potential Out-of-This-World Gains
Psychedelic drugs could be a major game-changer when it comes to treating mental illness. All as psilocybin, LSD, and MDMA show progress. 
Via InvestorPlace
MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter... 
Via Benzinga
Cannabis Movers & Shakers: Mind Medicine, Avant Brands, Delic, Agrify, Ascend Wellness, Pure Beauty
Mind Medicine Appoints Maria A. Oquendo To Scientific Advisory Board Psychedelic-focused biotech company Mind Medicine Inc. 
Via Benzinga
Topics Cannabis
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why. 
Via InvestorPlace
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
This Could Be The Next Multi-Billion AI Breakthrough
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 5, 2021 – There’s a massive announcement set to take place later this year, and it could change the $12 trillion... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat? 
Via Talk Markets
Topics Initial Public Offering
Psychedelics Offer Hope for Mental Disorders, Addiction
Via Investor Brand Network
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness
Courtesy of: MindMed The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored c... 
Via Benzinga
Magic Mushrooms and Ecstasy: New Treatment For Autism Spectrum Disorders?
Much like cannabis, psychedelics are catch... 
Via Benzinga
Topics Cannabis
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety
Image by 3D Animation Production Company from Pixabay The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team... 
Via Benzinga
Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race
Small Pharma Inc. (OTCQB:DMTTF) (TSXV: 
Via Benzinga
Developments with Ketamine Psychotherapy Are Driving A Medical Revolution For Treating Mental Health Issues
Palm Beach, FL –October 28, 2021 – FinancialNewsMedia.com News Commentary – Psychedelic drugs such as psilocybin, LSD and MDMA have tremendous medical and commercial future potential… and for ketamine,... 
Via FinancialNewsMedia
Topics Death Law Enforcement
Two Trillion-Dollar Industries Being Transformed By Tech
FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy.... 
Via FinancialNewsMedia
North America Continues Leading The Way In Psychedelic Wellness
Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing... 
Via FinancialNewsMedia
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.